Top

Published in:

Open Access 01-12-2022 | Ovarian Cancer | Review

RNA-binding proteins in ovarian cancer: a novel avenue of their roles in diagnosis and treatment

Authors: Jiangchun Wu, Yong Wu, Qinhao Guo, Simin Wang, Xiaohua Wu

Published in: Journal of Translational Medicine | Issue 1/2022

Abstract

Ovarian cancer (OC), an important cause of cancer-related death in women worldwide, is one of the most malignant cancers and is characterized by a poor prognosis. RNA-binding proteins (RBPs), a class of endogenous proteins that can bind to mRNAs and modify (or even determine) the amount of protein they can generate, have attracted great attention in the context of various diseases, especially cancers. Compelling studies have suggested that RBPs are aberrantly expressed in different cancer tissues and cell types, including OC tissues and cells. More specifically, RBPs can regulate proliferation, apoptosis, invasion, metastasis, tumorigenesis and chemosensitivity and serve as potential therapeutic targets in OC. Herein, we summarize what is currently known about the biogenesis, molecular functions and potential roles of human RBPs in OC and their prospects for application in the clinical treatment of OC.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics. CA Cancer J Clin. 2021;71(2021):7–33. https://doi.org/10.3322/caac.21654.CrossRef

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061. https://doi.org/10.1038/nrdp.2016.61.CrossRefPubMedPubMedCentral

Blagden S, Abdel Mouti M, Chettle J. Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer. Wiley Interdiscip Rev RNA. 2018. https://doi.org/10.1002/wrna.1432.CrossRefPubMed

Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016;13:255–61. https://doi.org/10.1038/nrclinonc.2015.224.CrossRefPubMed

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376–88. https://doi.org/10.1016/S0140-6736(13)62146-7.CrossRefPubMed

Mohibi S, Chen X, Zhang J. Cancer the’RBP’eutics-RNA-binding proteins as therapeutic targets for cancer. Pharmacol Ther. 2019;203:107390. https://doi.org/10.1016/j.pharmthera.2019.07.001.CrossRefPubMedPubMedCentral

Busa R, Paronetto MP, Farini D, Pierantozzi E, Botti F, Angelini DF, Attisani F, Vespasiani G, Sette C. The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene. 2007;26:4372–82. https://doi.org/10.1038/sj.onc.1210224.CrossRefPubMed

Yang G, Fu H, Zhang J, Lu X, Yu F, Jin L, Bai L, Huang B, Shen L, Feng Y, Yao L, Lu Z. RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology. 2010;138(231–240):e231-235. https://doi.org/10.1053/j.gastro.2009.08.001.CrossRef

Janiszewska M, Suva ML, Riggi N, Houtkooper RH, Auwerx J, Clement-Schatlo V, Radovanovic I, Rheinbay E, Provero P, Stamenkovic I. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012;26:1926–44. https://doi.org/10.1101/gad.188292.112.CrossRefPubMedPubMedCentral

10.

Guo Q, Wu Y, Guo X, Cao L, Xu F, Zhao H, Zhu J, Wen H, Ju X, Wu X. The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B. Mol Ther Nucleic Acids. 2021;23:169–84. https://doi.org/10.1016/j.omtn.2020.10.011.CrossRefPubMed

11.

Sternburg EL, Karginov FV. Global approaches in studying rna-binding protein interaction networks. Trends Biochem Sci. 2020;45:593–603. https://doi.org/10.1016/j.tibs.2020.03.005.CrossRefPubMed

12.

Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors, trends. Cancer. 2017;3:506–28. https://doi.org/10.1016/j.trecan.2017.05.003.CrossRef

13.

Zhou M, Wang X, Shi H, Cheng L, Wang Z, Zhao H, Yang L, Sun J. Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer. Oncotarget. 2016;7:12598–611. https://doi.org/10.18632/oncotarget.7181.CrossRefPubMedPubMedCentral

14.

Sebestyen E, Singh B, Minana B, Pages A, Mateo F, Pujana MA, Valcarcel J, Eyras E. Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Res. 2016;26:732–44. https://doi.org/10.1101/gr.199935.115.CrossRefPubMedPubMedCentral

15.

Bai Y, Qiu GR, Zhou F, Gong LY, Gao F, Sun KL. Overexpression of DICER1 induced by the upregulation of GATA1 contributes to the proliferation and apoptosis of leukemia cells. Int J Oncol. 2013;42:1317–24. https://doi.org/10.3892/ijo.2013.1831.CrossRefPubMed

16.

Abdelmohsen K, Tominaga-Yamanaka K, Srikantan S, Yoon JH, Kang MJ, Gorospe M. RNA-binding protein AUF1 represses Dicer expression. Nucleic Acids Res. 2012;40:11531–44. https://doi.org/10.1093/nar/gks930.CrossRefPubMedPubMedCentral

17.

Castello A, Fischer B, Eichelbaum K, Horos R, Beckmann BM, Strein C, Davey NE, Humphreys DT, Preiss T, Steinmetz LM, Krijgsveld J, Hentze MW. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012;149:1393–406. https://doi.org/10.1016/j.cell.2012.04.031.CrossRefPubMed

18.

He Q, Zhao L, Liu X, Zheng J, Liu Y, Liu L, Ma J, Cai H, Li Z, Xue Y. MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change. J Exp Clin Cancer Res. 2019;38:9. https://doi.org/10.1186/s13046-018-0990-1.CrossRefPubMedPubMedCentral

19.

Selvanathan SP, Graham GT, Erkizan HV, Dirksen U, Natarajan TG, Dakic A, Yu S, Liu X, Paulsen MT, Ljungman ME, Wu CH, Lawlor ER, Uren A, Toretsky JA. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Proc Natl Acad Sci U S A. 2015;112:E1307-1316. https://doi.org/10.1073/pnas.1500536112.CrossRefPubMedPubMedCentral

20.

Larsen JE, Nathan V, Osborne JK, Farrow RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A. ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. J Clin Invest. 2016;126:3219–35.CrossRef

21.

Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cel Biol. 2017;19:518–29. https://doi.org/10.1038/ncb3513.CrossRef

22.

Zhang J, Cho SJ, Shu L, Yan W, Guerrero T, Kent M, Skorupski K, Chen H, Chen X. Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. Genes Dev. 2011;25:1528–43. https://doi.org/10.1101/gad.2069311.CrossRefPubMedPubMedCentral

23.

Zhang J, Jun S, Chen X. RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc Natl Acad Sci USA. 2010;107:9614–9. https://doi.org/10.1073/pnas.0912594107.CrossRefPubMedPubMedCentral

24.

Abdelmohsen K, Kim MM, Srikantan S, Mercken EM, Brennan SE, Wilson GM, Cabo R, Gorospe M. miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle. 2010;9:1354–9. https://doi.org/10.4161/cc.9.7.11164.CrossRefPubMed

25.

Gao J, Dai C, Yu X, Yin XB, Zhou F. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway. J Cell Biochem. 2021;122:86–99. https://doi.org/10.1002/jcb.29833.CrossRefPubMed

26.

Yang LY, Song GL, Zhai XQ, Wang L, Liu QL, Zhou MS. MicroRNA-331 inhibits development of gastric cancer through targeting musashi1, World J Gastrointest. Oncol. 2019;11:705–16. https://doi.org/10.4251/wjgo.v11.i9.705.CrossRef

27.

Brown AS, Mohanty BK, Howe PH. Identification and characterization of an hnRNP E1 translational silencing motif. Nucleic Acids Res. 2016;44:5892–907. https://doi.org/10.1093/nar/gkw241.CrossRefPubMedPubMedCentral

28.

Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL, Howe PH. TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol. 2010;12:286–93. https://doi.org/10.1038/ncb2029.CrossRefPubMedPubMedCentral

29.

Babic I, Jakymiw A, Fujita DJ. The RNA binding protein Sam68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity. Oncogene. 2004;23:3781–9. https://doi.org/10.1038/sj.onc.1207484.CrossRefPubMed

30.

Neelamraju Y, Hashemikhabir S, Janga SC. The human RBPome: from genes and proteins to human disease. J Proteomics. 2015;127:61–70. https://doi.org/10.1016/j.jprot.2015.04.031.CrossRefPubMed

31.

Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev Genet. 2014;15:829–45. https://doi.org/10.1038/nrg3813.CrossRefPubMed

32.

Lunde BM, Moore C, Varani G. RNA-binding proteins: modular design for efficient function. Nat Rev Mol Cell Biol. 2007;8:479–90. https://doi.org/10.1038/nrm2178.CrossRefPubMedPubMedCentral

33.

Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2010;79:321–49. https://doi.org/10.1146/annurev-biochem-060208-105251.CrossRefPubMedPubMedCentral

34.

Moore S, Jarvelin AI, Davis I, Bond GL, Castello A. Expanding horizons: new roles for non-canonical RNA-binding proteins in cancer. Curr Opin Genet Dev. 2018;48:112–20. https://doi.org/10.1016/j.gde.2017.11.006.CrossRefPubMedPubMedCentral

35.

Kang D, Lee Y, Lee JS. RNA-binding proteins in cancer: functional and therapeutic perspectives. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12092699.CrossRefPubMedCentral

36.

Corley M, Burns MC, Yeo GW. How RNA-Binding Proteins Interact with RNA: Molecules and Mechanisms. Mol Cell. 2020;78:9–29. https://doi.org/10.1016/j.molcel.2020.03.011.CrossRefPubMedPubMedCentral

37.

Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat Rev Genet. 2016;17:19–32. https://doi.org/10.1038/nrg.2015.3.CrossRefPubMed

38.

Baralle FE, Giudice J. Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017;18:437–51. https://doi.org/10.1038/nrm.2017.27.CrossRefPubMedPubMedCentral

39.

Singh RK, Cooper TA. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med. 2012;18:472–82. https://doi.org/10.1016/j.molmed.2012.06.006.CrossRefPubMedPubMedCentral

40.

Anko ML. Regulation of gene expression programmes by serine-arginine rich splicing factors. Semin Cell Dev Biol. 2014;32:11–21. https://doi.org/10.1016/j.semcdb.2014.03.011.CrossRefPubMed

41.

Muller-McNicoll M, Botti V, de JesusDomingues AM, Brandl H, Schwich OD, Steiner MC, Curk T, Poser I, Zarnack K, Neugebauer KM. SR proteins are NXF1 adaptors that link alternative RNA processing to mRNA export. Genes Dev. 2016;30:553–66. https://doi.org/10.1101/gad.276477.115.CrossRefPubMedPubMedCentral

42.

Ortiz-Zapater E, Pineda D, Martinez-Bosch N, Fernandez-Miranda G, Iglesias M, Alameda F, Moreno M, Eliscovich C, Eyras E, Real FX, Mendez R, Navarro P. Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med. 2011;18:83–90. https://doi.org/10.1038/nm.2540.CrossRefPubMed

43.

Lazzaretti D, Bono F. mRNA localization in metazoans: A structural perspective. RNA Biol. 2017;14:1473–84. https://doi.org/10.1080/15476286.2017.1338231.CrossRefPubMedPubMedCentral

44.

Nagaoka K, Fujii K, Zhang H, Usuda K, Watanabe G, Ivshina M, Richter JD. CPEB1 mediates epithelial-to-mesenchyme transition and breast cancer metastasis. Oncogene. 2016;35:2893–901. https://doi.org/10.1038/onc.2015.350.CrossRefPubMed

45.

Nagaoka K, Udagawa T, Richter JD. CPEB-mediated ZO-1 mRNA localization is required for epithelial tight-junction assembly and cell polarity. Nat Commun. 2012;3:675. https://doi.org/10.1038/ncomms1678.CrossRefPubMed

46.

Chai Y, Liu J, Zhang Z, Liu L. HuR-regulated lncRNA NEAT1 stability in tumorigenesis and progression of ovarian cancer. Cancer Med. 2016;5:1588–98. https://doi.org/10.1002/cam4.710.CrossRefPubMedPubMedCentral

47.

Wang J, Guo Y, Chu H, Guan Y, Bi J, Wang B. Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int J Mol Sci. 2013;14:10015–41. https://doi.org/10.3390/ijms140510015.CrossRefPubMedPubMedCentral

48.

Sakuma T, Nakagawa T, Ido K, Takeuchi H, Sato K, Kubota T. Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas. J Neurooncol. 2008;88:143–55. https://doi.org/10.1007/s11060-008-9559-8.CrossRefPubMed

49.

Mayr C. Regulation by 3’-Untranslated Regions. Annu Rev Genet. 2017;51:171–94. https://doi.org/10.1146/annurev-genet-120116-024704.CrossRefPubMed

50.

Lal A, Mazan-Mamczarz K, Kawai T, Yang X, Martindale JL, Gorospe M. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J. 2004;23:3092–102. https://doi.org/10.1038/sj.emboj.7600305.CrossRefPubMedPubMedCentral

51.

Kessler SM, Lederer E, Laggai S, Golob-Schwarzl N, Hosseini K, Petzold J, Schweiger C, Reihs R, Keil M, Hoffmann J, Mayr C, Kiesslich T, Pichler M, Kim KS, Rhee H, Park YN, Lax S, Obrist P, Kiemer AK, Haybaeck J. IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer. Oncotarget. 2017;8:89736–45. https://doi.org/10.18632/oncotarget.21116.CrossRefPubMedPubMedCentral

52.

Bell JL, Wachter K, Muhleck B, Pazaitis N, Kohn M, Lederer M, Huttelmaier S. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 2013;70:2657–75. https://doi.org/10.1007/s00018-012-1186-z.CrossRefPubMed

53.

Medjkane S, Perez-Sanchez C, Gaggioli C, Sahai E, Treisman R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat Cell Biol. 2009;11:257–68. https://doi.org/10.1038/ncb1833.CrossRefPubMedPubMedCentral

54.

Kobel M, Weidensdorfer D, Reinke C, Lederer M, Schmitt WD, Zeng K, Thomssen C, Hauptmann S, Huttelmaier S. Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. Oncogene. 2007;26:7584–9. https://doi.org/10.1038/sj.onc.1210563.CrossRefPubMed

55.

Liao S, Sun H, Xu C, Domain YTH. A Family of N(6)-methyladenosine (m(6)A) Readers. Genomics Proteomics Bioinformatics. 2018;16:99–107. https://doi.org/10.1016/j.gpb.2018.04.002.CrossRefPubMedPubMedCentral

56.

Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, Cheng C, Li L, Pi J, Si Y, Xiao H, Li L, Rao S, Wang F, Yu J, Yu J, Zou D, Yi P. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48:3816–31. https://doi.org/10.1093/nar/gkaa048.CrossRefPubMedPubMedCentral

57.

Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. 2011;11:792–804. https://doi.org/10.1038/nrc3139.CrossRefPubMed

58.

Xu F, Li J, Ni M, Cheng J, Zhao H, Wang S, Zhou X, Wu X. FBW7 suppresses ovarian cancer development by targeting the N(6)-methyladenosine binding protein YTHDF2. Mol Cancer. 2021;20:45. https://doi.org/10.1186/s12943-021-01340-8.CrossRefPubMedPubMedCentral

59.

Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005;103:1631–43. https://doi.org/10.1002/cncr.20946.CrossRefPubMed

60.

Prislei S, Martinelli E, Zannoni GF, Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G, Scambia G, Ferlini C. Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer. Oncotarget. 2015;6:18966–79. https://doi.org/10.18632/oncotarget.3943.CrossRefPubMedPubMedCentral

61.

Wang Y, Katayama A, Terami T, Han X, Nunoue T, Zhang D, Teshigawara S, Eguchi J, Nakatsuka A, Murakami K, Ogawa D, Furuta Y, Makino H, Wada J. Translocase of inner mitochondrial membrane 44 alters the mitochondrial fusion and fission dynamics and protects from type 2 diabetes. Metabolism. 2015;64:677–88. https://doi.org/10.1016/j.metabol.2015.02.004.CrossRefPubMed

62.

Yu X, Li Y, Ding Y, Zhang H, Ding N, Lu M. HuR promotes ovarian cancer cell proliferation by regulating TIMM44 mRNA Stability. Cell Biochem Biophys. 2020;78:447–53. https://doi.org/10.1007/s12013-020-00939-w.CrossRefPubMed

63.

Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9:785–97. https://doi.org/10.1038/nrc2696.CrossRefPubMedPubMedCentral

64.

Zhang M, Xu Y, Zhang Y, Li B, Lou G. Circular RNA circE2F2 promotes malignant progression of ovarian cancer cells by upregulating the expression of E2F2 protein via binding to HuR protein. Cell Signal. 2021;84: 110014. https://doi.org/10.1016/j.cellsig.2021.110014.CrossRefPubMed

65.

Fonseca BD, Zakaria C, Jia JJ, Graber TE, Svitkin Y, Tahmasebi S, Healy D, Hoang HD, Jensen JM, Diao IT, Lussier A, Dajadian C, Padmanabhan N, Wang W, Matta-Camacho E, Hearnden J, Smith EM, Tsukumo Y, Yanagiya A, Morita M, Petroulakis E, Gonzalez JL, Hernandez G, Alain T, Damgaard CK. La-related Protein 1 (LARP1) Represses Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1 (mTORC1). J Biol Chem. 2015;290:15996–6020. https://doi.org/10.1074/jbc.M114.621730.CrossRefPubMedPubMedCentral

66.

Mura M, Hopkins TG, Michael T, Abd-Latip N, Weir J, Aboagye E, Mauri F, Jameson C, Sturge J, Gabra H, Bushell M, Willis AE, Curry E, Blagden SP. LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene. 2015;34:5025–36. https://doi.org/10.1038/onc.2014.428.CrossRefPubMed

67.

Hopkins TG, Mura M, Al-Ashtal HA, Lahr RM, Abd-Latip N, Sweeney K, Lu H, Weir J, El-Bahrawy M, Steel JH, Ghaem-Maghami S, Aboagye EO, Berman AJ, Blagden SP. The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Res. 2016;44:1227–46. https://doi.org/10.1093/nar/gkv1515.CrossRefPubMed

68.

Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease. Hum Genet. 2016;135:851–67. https://doi.org/10.1007/s00439-016-1683-5.CrossRefPubMedPubMedCentral

69.

Yang Y, Wei Q, Tang Y, Yuanyuan W, Luo Q, Zhao H, He M, Wang H, Zeng Q, Lu W, Xu J, Liu T, Yi P. Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer. Cancer Lett. 2020;475:43–52. https://doi.org/10.1016/j.canlet.2020.01.029.CrossRefPubMed

70.

Hsu KF, Shen MR, Huang YF, Cheng YM, Lin SH, Chow NH, Cheng SW, Chou CY, Ho CL. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer. 2015;113:414–24. https://doi.org/10.1038/bjc.2015.254.CrossRefPubMedPubMedCentral

71.

Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell. 2009;33:591–601. https://doi.org/10.1016/j.molcel.2009.01.025.CrossRefPubMedPubMedCentral

72.

Chen S, Wu W, Li QH, Xie BM, Shen F, Du YP, Zong ZH, Wang LL, Wei XQ, Zhao Y. Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression. Cell Death Discov. 2021;7:22. https://doi.org/10.1038/s41420-020-00381-0.CrossRefPubMedPubMedCentral

73.

Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R. The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432:235–40. https://doi.org/10.1038/nature03120.CrossRefPubMed

74.

Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425:415–9. https://doi.org/10.1038/nature01957.CrossRefPubMed

75.

Han C, Liu Y, Wan G, Choi HJ, Zhao L, Ivan C, He X, Sood AK, Zhang X, Lu X. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. Cell Rep. 2014;8:1447–60. https://doi.org/10.1016/j.celrep.2014.07.058.CrossRefPubMedPubMedCentral

76.

Li J, Wu L, Pei M, Zhang Y. YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells. J Ovarian Res. 2020;13:111. https://doi.org/10.1186/s13048-020-00717-5.CrossRefPubMedPubMedCentral

77.

Ehlen A, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-Kristensson M, Ponten F, Brennan DJ, Jirstrom K. RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Transl Oncol. 2011;4:212–21. https://doi.org/10.1593/tlo.11106.CrossRefPubMedPubMedCentral

78.

Shi H, Li H, Yuan R, Guan W, Zhang X, Zhang S, Zhang W, Tong F, Li L, Song Z, Wang C, Yang S, Wang H. PCBP1 depletion promotes tumorigenesis through attenuation of p27(Kip1) mRNA stability and translation. J Exp Clin Cancer Res. 2018;37:187. https://doi.org/10.1186/s13046-018-0840-1.CrossRefPubMedPubMedCentral

79.

Arslan O, Soylu NK, Akillilar PT, Tazebay UH. Coiled-coil domain-containing protein-124 (Ccdc124) is a novel RNA binding factor up-regulated in endometrial, ovarian, and urinary bladder cancers. Cancer Biomark. 2021;31:149–64. https://doi.org/10.3233/CBM-200802.CrossRefPubMed

80.

Bi F, An Y, Sun T, You Y, Yang Q. PHGDH Is Upregulated at Translational Level and Implicated in Platin-Resistant in Ovarian Cancer Cells. Front Oncol. 2021;11: 643129. https://doi.org/10.3389/fonc.2021.643129.CrossRefPubMedPubMedCentral

81.

Ni J, Chen L, Ling L, Wu M, Ren Q, Zhu W. MicroRNA-196a promotes cell proliferation and inhibits apoptosis in human ovarian cancer by directly targeting DDX3 and regulating the PTEN/PI3K/AKT signaling pathway. Mol Med Rep. 2020;22:1277–84. https://doi.org/10.3892/mmr.2020.11236.CrossRefPubMedPubMedCentral

82.

Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1–22. https://doi.org/10.1002/(sici)1097-0215(19970703)72:1%3c1::aid-ijc1%3e3.0.co;2-z.CrossRefPubMed

83.

Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. Gynecol Oncol. 2007;107:266–73. https://doi.org/10.1016/j.ygyno.2007.06.023.CrossRefPubMed

84.

Zhong Y, Yang S, Wang W, Wei P, He S, Ma H, Yang J, Wang Q, Cao L, Xiong W, Zhou M, Li G, Shuai C, Peng S. The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer. Oncogene. 2019;38:1381–97. https://doi.org/10.1038/s41388-018-0512-9.CrossRefPubMed

85.

Lin X, Shen J, Dan P, He X, Xu C, Chen X, Tanyi JL, Montone K, Fan Y, Huang Q, Zhang L, Zhong X. RNA-binding protein LIN28B inhibits apoptosis through regulation of the AKT2/FOXO3A/BIM axis in ovarian cancer cells. Signal Transduct Target Ther. 2018;3:23. https://doi.org/10.1038/s41392-018-0026-5.CrossRefPubMedPubMedCentral

86.

Yong W, Yu D, Jun Z, Yachen D, Weiwei W, Midie X, Xingzhu J, Xiaohua W. Long noncoding RNA NEAT1, regulated by LIN28B, promotes cell proliferation and migration through sponging miR-506 in high-grade serous ovarian cancer. Cell Death Dis. 2018;9:861. https://doi.org/10.1038/s41419-018-0908-z.CrossRefPubMedPubMedCentral

87.

Wollerton MC, Gooding C, Wagner EJ, Garcia-Blanco MA, Smith CW. Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. Mol Cell. 2004;13:91–100. https://doi.org/10.1016/s1097-2765(03)00502-1.CrossRefPubMed

88.

He X, Pool M, Darcy KM, Lim SB, Auersperg N, Coon JS, Beck WT. Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene. 2007;26:4961–8. https://doi.org/10.1038/sj.onc.1210307.CrossRefPubMedPubMedCentral

89.

Muller S, Glass M, Singh AK, Haase J, Bley N, Fuchs T, Lederer M, Dahl A, Huang H, Chen J, Posern G, Huttelmaier S. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic Acids Res. 2019;47:375–90. https://doi.org/10.1093/nar/gky1012.CrossRefPubMed

90.

He C, Huang F, Zhang K, Wei J, Hu K, Liang M. Establishment and validation of an RNA binding protein-associated prognostic model for ovarian cancer. J Ovarian Res. 2021;14:27. https://doi.org/10.1186/s13048-021-00777-1.CrossRefPubMedPubMedCentral

91.

Zhang Z, Cheng J, Wu Y, Qiu J, Sun Y, Tong X. LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer. Mol Med Rep. 2016;14:2465–72. https://doi.org/10.3892/mmr.2016.5572.CrossRefPubMedPubMedCentral

92.

Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, Shahabi S, Scambia G, Ferlini C. MiR-200c and HuR in ovarian cancer. BMC Cancer. 2013;13:72. https://doi.org/10.1186/1471-2407-13-72.CrossRefPubMedPubMedCentral

93.

Li Q, Zhang C, Chen R, Xiong H, Qiu F, Liu S, Zhang M, Wang F, Wang Y, Zhou X, Xiao G, Wang X, Jiang Q. Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma. Cancer Lett. 2016;383:28–40. https://doi.org/10.1016/j.canlet.2016.09.019.CrossRefPubMed

94.

Weidle UH, Birzele F, Kollmorgen G, Ruger R. Long Non-coding RNAs and their Role in Metastasis. Cancer Genomics Proteomics. 2017;14:143–60. https://doi.org/10.21873/cgp.20027.CrossRefPubMedPubMedCentral

95.

Wu D, Ke Y, Xiao R, Liu J, Li Q, Wang Y. Long non-coding RNA GClnc1 knockdown suppresses progression of epithelial ovarian cancer by recruiting FOXC2 to disrupt the NOTCH1/NF-kappaB/Snail pathway. Exp Cell Res. 2021;399: 112422. https://doi.org/10.1016/j.yexcr.2020.112422.CrossRefPubMed

96.

Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 2019;58:196–205. https://doi.org/10.1002/mc.22919.CrossRefPubMed

97.

Sanger JM, Wang J, Gleason LM, Chowrashi P, Dube DK, Mittal B, Zhukareva V, Sanger JW. Arg/Abl-binding protein, a Z-body and Z-band protein, binds sarcomeric, costameric, and signaling molecules. Cytoskeleton (Hoboken). 2010;67:808–23. https://doi.org/10.1002/cm.20490.CrossRef

98.

Kimura A, Baumann CA, Chiang SH, Saltiel AR. The sorbin homology domain: a motif for the targeting of proteins to lipid rafts. Proc Natl Acad Sci U S A. 2001;98:9098–103. https://doi.org/10.1073/pnas.151252898.CrossRefPubMedPubMedCentral

99.

Zhao L, Wang W, Huang S, Yang Z, Xu L, Yang Q, Zhou X, Wang J, Shen Q, Wang C, Le X, Feng M, Zhou N, Lau WB, Lau B, Yao S, Yi T, Wang X, Zhao X, Wei Y, Zhou S. The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts. Genome Biol. 2018;19:35. https://doi.org/10.1186/s13059-018-1412-6.CrossRefPubMedPubMedCentral

100.

Liu T, Yang Y, Xie Z, Luo Q, Yang D, Liu X, Zhao H, Wei Q, Liu Y, Li L, Wang Y, Wang F, Yu J, Xu J, Yu J, Yi P. The RNA binding protein QKI5 suppresses ovarian cancer via downregulating transcriptional coactivator TAZ. Mol Ther Nucleic Acids. 2021;26:388–400. https://doi.org/10.1016/j.omtn.2021.07.012.CrossRefPubMedPubMedCentral

101.

Weidensdorfer D, Stohr N, Baude A, Lederer M, Kohn M, Schierhorn A, Buchmeier S, Wahle E, Huttelmaier S. Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. RNA. 2009;15:104–15. https://doi.org/10.1261/rna.1175909.CrossRefPubMedPubMedCentral

102.

Knott GJ, Bond CS, Fox AH. The DBHS proteins SFPQ, NONO and PSPC1: a multipurpose molecular scaffold. Nucleic Acids Res. 2016;44:3989–4004. https://doi.org/10.1093/nar/gkw271.CrossRefPubMedPubMedCentral

103.

Pellarin I, Dall’Acqua A, Gambelli A, Pellizzari I, D’Andrea S, Sonego M, Lorenzon I, Schiappacassi M, Belletti B, Baldassarre G. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity. Oncogene. 2020;39:4390–403. https://doi.org/10.1038/s41388-020-1292-6.CrossRefPubMedPubMedCentral

104.

Zhang Y, Gan H, Zhao F, Ma X, Xie X, Huang R, Zhao J. CPEB4-Promoted Paclitaxel Resistance in Ovarian Cancer In Vitro Relies on Translational Regulation of CSAG2. Front Pharmacol. 2020;11: 600994. https://doi.org/10.3389/fphar.2020.600994.CrossRefPubMed

105.

Yang X, Potts PR. CSAG2 is a cancer-specific activator of SIRT1. EMBO Rep. 2020;21: e50912. https://doi.org/10.15252/embr.202050912.CrossRefPubMedPubMedCentral

106.

Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K, Kuwano M, Nakano H. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol. 2002;128:621–6. https://doi.org/10.1007/s00432-002-0386-6.CrossRefPubMed

107.

Danno S, Nishiyama H, Higashitsuji H, Yokoi H, Xue JH, Itoh K, Matsuda T, Fujita J. Increased transcript level of RBM3, a member of the glycine-rich RNA-binding protein family, in human cells in response to cold stress. Biochem Biophys Res Commun. 1997;236:804–7. https://doi.org/10.1006/bbrc.1997.7059.CrossRefPubMed

108.

Prawira A, Munusamy P, Yuan J, Chan CHT, Koh GL, Shuen TWH, Hu J, Yap YS, Tan MH, Ang P, Lee ASG. Assessment of PARP4 as a candidate breast cancer susceptibility gene. Breast Cancer Res Treat. 2019;177:145–53. https://doi.org/10.1007/s10549-019-05286-w.CrossRefPubMed

109.

Manoharan R, Seong HA, Ha H. Dual Roles of Serine-Threonine Kinase Receptor-Associated Protein (STRAP) in Redox-Sensitive Signaling Pathways Related to Cancer Development. Oxid Med Cell Longev. 2018;2018:5241524. https://doi.org/10.1155/2018/5241524.CrossRefPubMedPubMedCentral

110.

Antony F, Deantonio C, Cotella D, Soluri MF, Tarasiuk O, Raspagliesi F, Adorni F, Piazza S, Ciani Y, Santoro C, Macor P, Mezzanzanica D, Sblattero D. High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. Oncoimmunology. 2019;8: e1614856. https://doi.org/10.1080/2162402X.2019.1614856.CrossRefPubMedPubMedCentral

111.

Visconte V. Mutations in splicing factor genes in myeloid malignancies: significance and impact on clinical features. Cancers (Basel). 2019. https://doi.org/10.3390/cancers11121844.CrossRef

112.

Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, Kommoss S, Leung SCY, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, George J, Fereday S, Hendley J, Traficante N, Steed H, Koziak JM, Kobel M, McNeish IA, Goranova T, Ennis D, Macintyre G, Silva D, Ramon YCT, Garcia-Donas J, HernandoPolo S, Rodriguez GC, Cushing-Haugen KL, Harris HR, Greene CS, Zelaya RA, Behrens S, Fortner RT, Sinn P, Herpel E, Lester J, Lubinski J, Oszurek O, Toloczko A, Cybulski C, Menkiszak J, Pearce CL, Pike MC, Tseng C, Alsop J, Rhenius V, Song H, Jimenez-Linan M, Piskorz AM, Gentry-Maharaj A, Karpinskyj C, Widschwendter M, Singh N, Kennedy CJ, Sharma R, Harnett PR, Gao B, Johnatty SE, Sayer R, Boros J, Winham SJ, Keeney GL, Kaufmann SH, Larson MC, Luk H, Hernandez BY, Thompson PJ, Wilkens LR, Carney ME, Trabert B, Lissowska J, Brinton L, Sherman ME, Bodelon C, Hinsley S, Lewsley LA, Glasspool R, Banerjee SN, Stronach EA, Haluska P, Ray-Coquard I, Mahner S, Winterhoff B, Slamon D, Levine DA, Kelemen LE, Benitez J, Chang-Claude J, Gronwald J, Wu AH, Menon U, Goodman MT, Schildkraut JM, Wentzensen N, Brown R, Berchuck A, Chenevix-Trench G, Fazio A, Gayther SA, Garcia MJ, Henderson MJ, Rossing MA, Beeghly-Fadiel A, Fasching PA, Orsulic S, Karlan BY, Konecny GE, Huntsman DG, Bowtell DD, Brenton JD, Doherty JA, Pharoah PDP, Ramus SJ. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020;31:1240–50. https://doi.org/10.1016/j.annonc.2020.05.019.CrossRefPubMed

113.

Wang K, Li L, Fu L, Yuan Y, Dai H, Zhu T, Zhou Y, Yuan F. Integrated Bioinformatics Analysis the Function of RNA Binding Proteins (RBPs) and their prognostic value in breast cancer. Front Pharmacol. 2019;10:140. https://doi.org/10.3389/fphar.2019.00140.CrossRefPubMedPubMedCentral

114.

Li W, Gao LN, Song PP, You CG. Development and validation of a RNA binding protein-associated prognostic model for lung adenocarcinoma. Aging. 2020;12:3558–73. https://doi.org/10.18632/aging.102828.CrossRefPubMedPubMedCentral

115.

Zhao L, Cao J, Hu K, Wang P, Li G, He X, Tong T, Han L. RNA-binding protein RPS3 contributes to hepatocarcinogenesis by post-transcriptionally up-regulating SIRT1. Nucleic Acids Res. 2019;47:2011–28. https://doi.org/10.1093/nar/gky1209.CrossRefPubMed

116.

Zhang Z, Wang L, Wang Q, Zhang M, Wang B, Jiang K, Ye Y, Wang S, Shen Z. Molecular characterization and clinical relevance of RNA Binding Proteins in Colorectal Cancer. Front Genet. 2020;11: 580149. https://doi.org/10.3389/fgene.2020.580149.CrossRefPubMedPubMedCentral

117.

Fan L, Lin Y, Lei H, Shu G, He L, Yan Z, Rihan H, Yin G. A newly defined risk signature, consisting of three m(6)A RNA methylation regulators, predicts the prognosis of ovarian cancer. Aging. 2020;12:18453–75. https://doi.org/10.18632/aging.103811.CrossRefPubMedPubMedCentral

118.

Lucchesi CA, Zhang J, Ma B, Chen M, Chen X. Disruption of the Rbm38-eIF4E Complex with a Synthetic Peptide Pep8 Increases p53 Expression. Cancer Res. 2019;79:807–18. https://doi.org/10.1158/0008-5472.CAN-18-2209.CrossRefPubMed

119.

Ko SY, Guo H, Barengo N, Naora H. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res. 2009;15:4336–47. https://doi.org/10.1158/1078-0432.CCR-08-2924.CrossRefPubMed

120.

Chen H, Liu J, Wang H, Cheng Q, Zhou C, Chen X, Ye F. Inhibition of RNA-binding protein musashi-1 suppresses malignant properties and reverses paclitaxel resistance in ovarian carcinoma. J Cancer. 2019;10:1580–92. https://doi.org/10.7150/jca.27352.CrossRefPubMedPubMedCentral

121.

Fu C, Yuan M, Sun J, Liu G, Zhao X, Chang W, Ma Z. RNA-Binding Motif Protein 11 (RBM11) serves as a prognostic biomarker and promotes ovarian cancer progression. Dis Markers. 2021;2021:3037337. https://doi.org/10.1155/2021/3037337.CrossRefPubMedPubMedCentral

122.

Wang S, Li Z, Zhu G, Hong L, Hu C, Wang K, Cui K, Hao C. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis. J Ovarian Res. 2021;14:154. https://doi.org/10.1186/s13048-021-00917-7.CrossRefPubMedPubMedCentral

123.

Zhao H, Gao Y, Chen Q, Li J, Ren M, Zhao X, Yue W. RAD51AP1 promotes progression of ovarian cancer via TGF-beta/Smad signalling pathway. J Cell Mol Med. 2021;25:1927–38. https://doi.org/10.1111/jcmm.15877.CrossRefPubMed

124.

Wang L, Rowe RG, Jaimes A, Yu C, Nam Y, Pearson DS, Zhang J, Xie X, Marion W, Heffron GJ, Daley GQ, Sliz P. Small-molecule inhibitors disrupt let-7 oligouridylation and release the selective blockade of let-7 processing by LIN28. Cell Rep. 2018;23:3091–101. https://doi.org/10.1016/j.celrep.2018.04.116.CrossRefPubMedPubMedCentral

125.

Hiramatsu K, Yoshino K, Serada S, Yoshihara K, Hori Y, Fujimoto M, Matsuzaki S, Egawa-Takata T, Kobayashi E, Ueda Y, Morii E, Enomoto T, Naka T, Kimura T. Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas. Br J Cancer. 2016;114:554–61. https://doi.org/10.1038/bjc.2016.27.CrossRefPubMedPubMedCentral

126.

Hao L, Wang JM, Liu BQ, Yan J, Li C, Jiang JY, Zhao FY, Qiao HY, Wang HQ. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim Biophys Acta Mol Cell Res. 2021;1868: 118878. https://doi.org/10.1016/j.bbamcr.2020.118878.CrossRefPubMed

Title: RNA-binding proteins in ovarian cancer: a novel avenue of their roles in diagnosis and treatment
Authors: Jiangchun Wu
Yong Wu
Qinhao Guo
Simin Wang
Xiaohua Wu
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-022-03245-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Total mutational load and clinical features as predictors of the metastatic status in lung adenocarcinoma and squamous cell carcinoma patients

Transcriptome-based network analysis related to M2-like tumor-associated macrophage infiltration identified VARS1 as a potential target for improving melanoma immunotherapy efficacy

Multi-scale pathology image texture signature is a prognostic factor for resectable lung adenocarcinoma: a multi-center, retrospective study

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

Association between triglyceride-to-high-density lipoprotein cholesterol ratio and prediabetes: a cross-sectional study in Chinese non-obese people with a normal range of low-density lipoprotein cholesterol

Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage